Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 72 matching trials from the live ClinicalTrials.gov search.
Conditions
Essential Tremor of the Upper Limb
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more
Conditions
Provoked Vestibulodynia
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Conditions
Stroke
Interventions
Xeomin®
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers

Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

NCT05039723
Conditions
Photoaging
Interventions
Radiesse, Xeomin, Belotero
Drug
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
22 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Not listed Phase 2 Interventional Accepts healthy volunteers

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

NCT06034288
Conditions
Overactive Bladder Syndrome
Interventions
Xeomin 100 UNT Injection, Botox 100 UNT Injection
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo, Botulinum Toxin A - Open Label
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Encinitas, California • Aventura, Florida • Sarasota, Florida + 4 more
Conditions
Muscle Spasticity, Multiple Sclerosis
Interventions
incabotulinumtoxinA, Placebo
Biological
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Latham, New York
Conditions
Traumatic Brain Injury
Interventions
BoNT A
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Post-stroke Spasticity of the Lower Limb
Interventions
IncobotulinumtoxinA (400 Units), Placebo Comparator
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more
Conditions
Esophageal Carcinoma
Interventions
Botulinum Toxin Type A, Esophagectomy, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Completed Phase 2 Interventional Results available

Botulinum Toxin Injection for the Management of BPH

NCT00451191
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin type A (BoNT/A)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Rochester, Minnesota + 4 more
Completed Phase 4 Interventional Results available

The Treatment of Glabellar Frown Lines

NCT02096081
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA, OnabotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 6 more
Conditions
Skin Aging, Elastosis Senilis
Interventions
incobotulinumtoxinA
Biological
Lead sponsor
The Maas Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Cosmetic Techniques
Interventions
Onabotulinumtoxina for Injection, Abobotulinumtoxina for Injection, IncobotulinumtoxinA for Injection, PrabotulinumtoxinA for Injection
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more
Conditions
Episodic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
Conditions
Rosacea
Interventions
IncobotulinumtoxinA, Bacteriostatic saline
Drug
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Conditions
Glabellar Frown Lines
Interventions
QM1114-DP, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
9
States / cities
Homewood, Alabama • Manhattan Beach, California • Vista, California + 6 more
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more
Conditions
Cervical Dystonia
Interventions
incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas